Bard Logo

Investor Relations

BCR (Common Stock)
ExchangeNYSE (US Dollar)
Price$168.30
Change (%) Stock is Down 0.84 (0.50%)
Volume891,048
Data as of 03/02/15 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Featured Reports
Download Documentation2014 Proxy Statement
Download Documentation2013 Annual Report
Related Links
Corporate Governance
Contact the Bard Board of Directors
Recent NewsMore >>
DateTitle 
02/25/15Bard to Present at Raymond James Institutional Investors Conference
MURRAY HILL, N.J.--(BUSINESS WIRE)--Feb. 25, 2015-- C. R. Bard, Inc. (NYSE:BCR) today announced that it will present at the Raymond James Institutional Investors Conference in Orlando, Florida on March 4, 2015. Christopher S. Holland, senior vice president and chief financial officer, will discuss the Company in a presentation scheduled to begin at 11:00 AM Eastern Standard Time. A live webcast of Bard's presentation will be accessible to all ... 
Printer Friendly Version
02/19/15CMS Approves Pass-Through Payment for Lutonix DCB for Outpatient Use
MURRAY HILL, N.J.--(BUSINESS WIRE)--Feb. 19, 2015-- C. R. Bard, Inc. (NYSE:BCR) today announced that the U.S. Centers for Medicare and Medicaid Services (CMS) has approved a pass-through payment for the Lutonix® drug-coated balloon (DCB) under the Medicare hospital outpatient prospective payment system. This approval follows a unanimous favorable recommendation from the FDA’s Circulatory Systems Devices Advisory Panel, which voted 9 to 0 on each question... 
Printer Friendly Version
02/09/15Boston Scientific And C. R. Bard Announce Distribution Agreement For Lutonix® Drug Coated Balloon
Agreement Extends Reach of Lutonix DCB and Provides Physicians with a Comprehensive Solution to Prepare and Treat Diseased Femoropopliteal Vessels MARLBOROUGH, Mass., and MURRAY HILL, N.J., Feb. 9, 2015 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) and C. R. Bard, Inc. (NYSE: BCR) ("Bard") today announced that Boston Scientific will distribute the Lutonix® 035 Drug Coated Balloon Percutaneous Transluminal Angioplasty Catheter (Lutonix DCB) in the United States under a limit... 
Printer Friendly Version
01/29/15Bard Announces Fourth Quarter Results
MURRAY HILL, N.J.--(BUSINESS WIRE)--Jan. 29, 2015-- C. R. Bard, Inc. (NYSE:BCR) today reported 2014 fourth quarter financial results. Fourth quarter 2014 net sales were $867.2 million, an increase of 10 percent over the prior-year period on an as-reported basis. Excluding the impact of foreign exchange, fourth quarter 2014 net sales increased 11 percent over the prior-year period. For the fourth quarter 2014, net sales in the U.S. were $591.6 mil... 
Printer Friendly Version
Selected SEC Filings
Filing DateForm
02/18/1510-K Download SEC Filing to Adobe PDF Download XBRL Content
10/23/1410-Q Download SEC Filing to Adobe PDF Download XBRL Content
07/25/1410-Q Download SEC Filing to Adobe PDF Download XBRL Content
04/23/1410-Q Download SEC Filing to Adobe PDF Download XBRL Content
02/19/1410-K Download SEC Filing to Adobe PDF Download XBRL Content
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever C. R. Bard, Inc. posts new information to the site. Just enter your e-mail address and click Submit.
 

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.